Cidara Therapeutics, Inc.
CDTX
$22.36
-$0.64-2.78%
| Weiss Ratings | CDTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CDTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CDTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.42 | |||
| Price History | CDTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.45% | |||
| 30-Day Total Return | 25.27% | |||
| 60-Day Total Return | 3.33% | |||
| 90-Day Total Return | 74.28% | |||
| Year to Date Total Return | -18.10% | |||
| 1-Year Total Return | 68.12% | |||
| 2-Year Total Return | -35.38% | |||
| 3-Year Total Return | 64.00% | |||
| 5-Year Total Return | -51.18% | |||
| 52-Week High % Change | -19.07% | |||
| 52-Week Low % Change | 129.91% | |||
| Price | CDTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $28.42 | |||
| 52-Week Low Price | $10.00 | |||
| 52-Week Low Price (Date) | Apr 22, 2024 | |||
| 52-Week High Price (Date) | Jan 02, 2025 | |||
| Valuation | CDTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 251.93M | |||
| Enterprise Value | 65.68M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -25.43 | |||
| Earnings Per Share Growth | 180.85% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 37.27 | |||
| Price/Book (Q) | 1.40 | |||
| Enterprise Value/Revenue (TTM) | 16.29 | |||
| Price | $22.36 | |||
| Enterprise Value/EBITDA (TTM) | -1.44 | |||
| Enterprise Value/EBIT | -1.44 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | CDTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 6.53M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CDTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 752 6170 | |||
| Address | 6310 Nancy Ridge Drive San Diego, CA 92121 | |||
| Website | www.cidara.com | |||
| Country | United States | |||
| Year Founded | 2012 | |||
| Profitability | CDTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,134.65% | |||
| Profit Margin | -2,995.11% | |||
| Management Effectiveness | CDTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -25.32% | |||
| Return on Equity | -- | |||
| Income Statement | CDTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 4.03M | |||
| Total Revenue (TTM) | 4.03M | |||
| Revenue Per Share | $0.62 | |||
| Gross Profit (TTM) | -28.98M | |||
| EBITDA (TTM) | -45.59M | |||
| EBIT (TTM) | -45.74M | |||
| Net Income (TTM) | -120.73M | |||
| Net Income Avl. to Common (TTM) | -120.73M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -306.36% | |||
| EPS Diluted (TTM) | -25.43 | |||
| EPS Diluted Growth (Q YOY) | -21.20% | |||
| Balance Sheet | CDTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 127.39M | |||
| Cash Per Share (Q) | $19.51 | |||
| Total Current Assets (Q) | 156.77M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 115.63M | |||
| Current Ratio (Q) | 3.536 | |||
| Book Value Per Share (Q) | $16.41 | |||
| Total Assets (Q) | 162.33M | |||
| Total Current Liabilities (Q) | 44.34M | |||
| Total Debt (Q) | 3.94M | |||
| Total Liabilities (Q) | 46.70M | |||
| Total Common Equity (Q) | 115.63M | |||
| Cash Flow | CDTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -307.00K | |||
| Cash from Financing (TTM) | -267.00K | |||
| Net Change in Cash (TTM) | -56.64M | |||
| Levered Free Cash Flow (TTM) | -19.65M | |||
| Cash from Operations (TTM) | -56.06M | |||
